Patents by Inventor Christoph Stephan

Christoph Stephan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DIAMINOHETEROARYL SUBSTITUTED PYRAZOLES
    Publication number: 20160145239
    Abstract: Compounds of formula (I), and their use as pharmaceuticals.
    Type: Application
    Filed: June 17, 2014
    Publication date: May 26, 2016
    Inventors: Christoph-Stephan HILGER, Marion HITCHCOCK, Hans BRIEM, Gerhard SIEMEISTER, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Simon HOLTON, Comelia PREUßE, Karsten DENNER
  • Substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one
    Patent number: 9278925
    Abstract: The invention relates to substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-ones, in particular for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of neoplastic disorders.
    Type: Grant
    Filed: July 31, 2012
    Date of Patent: March 8, 2016
    Assignee: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ningshu Liu, Kai Thede, Ursula Mönning, Arne Scholz, Christoph-Stephan Hilger, Ulf Bömer, Reiner Fischer
  • DIAMINOHETEROARYL SUBSTITUTED INDAZOLES
    Publication number: 20160052912
    Abstract: Compounds of formula (I) which are inhibitors of Bub 1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: March 19, 2014
    Publication date: February 25, 2016
    Inventors: Christoph-Stephan HILGER, Marion HITCHCOCK, Hans BRIEM, Gerhard SIEMEISTER, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Simon HOLTON, Cornelia PREUßE, Karsten DENNER
  • HETEROARYL SUBSTITUTED INDAZOLES
    Publication number: 20160046604
    Abstract: Compounds of formula (I), which are inhibitors of Bub1 kinase, processes for their production and their use as pharmaceuticals.
    Type: Application
    Filed: March 20, 2014
    Publication date: February 18, 2016
    Inventors: Marion HITCHCOCK, Anne MENGEL, Christoph-Stephan HILGER, Lars BÄRFACKER, Hans BRIEM, Gerhard SIEMEISTER, Amaury Ernesto FERNANDEZ-MONTALVAN, Jens SCHRÖDER, Simon HOLTON, Cornelia PREUßE, Ursula MÖNNING
  • (5s,8s)-3-(4?-chlor-3?-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5] dec-3-en-2-one (compound A) for treatment
    Patent number: 9212140
    Abstract: The invention relates to (5s,8s)-3-(4?-chloro-3?-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of tumour disorders.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: December 15, 2015
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ningshu Liu, Kai Thede, Philip Lienau, Arne Scholz, Christoph-Stephan Hilger, Ulf Bömer, Maher Najjar, Knut Eis, Reiner Fischer, Wahed Ahmed Moradi
  • SUBSTITUTED CYCLOALKENOPYRAZOLES AS BUB1 INHIBITORS FOR THE TREATMENT OF CANCER
    Publication number: 20150141372
    Abstract: Compounds of formula (I), processes for their production and their use as Bub1 kinase inhibitors for the treatment of hyperproliferative diseases and/or disorders responsive to induction of cell death.
    Type: Application
    Filed: May 8, 2013
    Publication date: May 21, 2015
    Inventors: Marion Hitchcock, Christoph-Stephan Hilger, Anne Mengel, Hans Briem, Simon Holton, Vera Pütter, Gerhard Siemeister, Stefan Prechtl, Amaury Ernesto Fernández-Montalván, Christian Stegmann, Cornelia Preuße, Mark Jean Gnoth
  • Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy
    Patent number: 9000026
    Abstract: The invention relates to substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones of the formula (Ia) for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of tumor disorders. The invention also relates to novel compounds of the formula (I) in which W, X, Y, Z, A, B, D and G have the meanings given above, to a plurality of processes and intermediates for their preparation, and to their use as pesticides and/or herbicides and/or fungicides. The invention also relates to selectively herbicidal compositions comprising, firstly, the halogen-substituted spirocyclic ketoenols and, secondly, a crop plant compatibility-improving compound.
    Type: Grant
    Filed: February 14, 2012
    Date of Patent: April 7, 2015
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Ningshu Liu, Kai Thede, Ursula Mönning, Arne Scholz, Christoph-Stephan Hilger, Ulf Bömer, Reiner Fischer
  • SUBSTITUTED 3-(BIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE
    Publication number: 20140275199
    Abstract: The invention relates to substituted 3-(biphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-ones, in particular for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of neoplastic disorders.
    Type: Application
    Filed: July 31, 2012
    Publication date: September 18, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ningshu Liu, Kai Thede, Ursula Mönning, Arne Scholz, Christoph-Stephan Hilger, Ulf Bömer, Reiner Fischer
  • (5S,8S)-3-(4'-CHLOR-3'-FLUOR-4-METHLYBIPHENYL-3-YL)-4-HYDROXY-8-METHOXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONE (COMPOUND A) FOR TREATMENT
    Publication number: 20140031407
    Abstract: The invention relates to (5s,8s)-3-(4?-chloro-3?-fluoro-4-methylbiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of tumour disorders.
    Type: Application
    Filed: February 3, 2012
    Publication date: January 30, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ningshu Liu, Kai Thede, Philip Lienau, Arne Scholz, Christoph-Stephan Hilger, Ulf Bömer, Maher Najjar, Knut Eis, Reiner Fischer, Wahed Ahmed Moradi
  • SUBSTITUTED 3-(BIPHENYL-3-YL)-8,8-DIFLUORO-4-HYDROXY-1-AZASPIRO[4.5]DEC-3-EN-2-ONES FOR THERAPY
    Publication number: 20140011853
    Abstract: The invention relates to substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones of the formula (Ia) for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of tumour disorders. The invention also relates to novel compounds of the formula (I) in which W, X, Y, Z, A, B, D and G have the meanings given above, to a plurality of processes and intermediates for their preparation, and to their use as pesticides and/or herbicides and/or fungicides. The invention also relates to selectively herbicidal compositions comprising, firstly, the halogen-substituted spirocyclic ketoenols and, secondly, a crop plant compatibility-improving compound.
    Type: Application
    Filed: February 14, 2012
    Publication date: January 9, 2014
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ningshu Liu, Kai Thede, Ursula Mönning, Arne Scholz, Christoph-Stephan Hilger, Ulf Bömer, Reiner Fischer
  • Selective targeting of tumor vasculature using antibody molecules
    Patent number: 8491906
    Abstract: The present invention relates to selectively targeting tumoral vasculature in vivo using a human recombinant scFv, L19, to the angiogenesis marker ED-B domain of fibronectin. In preferred embodiments, a complete human IgG1 is employed having the variable regions of L19. In other preferred embodiments is employed a mini-immunoglobulin generated by fusing the scFv L19 to the constant CH4 domain of a secretory IgE isoform that naturally contains a cysteine in its COOH terminal and which forms a covalently linked dimer. Different in vivo behavior of the antibody formats is exploitable for different diagnostic and/or therapeutic purposes, depending on clinical needs and disease. The antibody molecules may be labelled as described.
    Type: Grant
    Filed: March 11, 2003
    Date of Patent: July 23, 2013
    Assignees: Philogen S.p.A., Bayer Schering Pharma AG
    Inventors: Laura Borsi, Barbara Carnemolla, Enrica Balza, Patrizia Castellani, Luciano Zardi, Matthias Friebe, Christoph-Stephan Hilger
  • CYCLIC KETO-ENOLS FOR THERAPY
    Publication number: 20130040935
    Abstract: The invention relates to 5?-biphenyl-substituted cyclic ketoenols for therapeutic purposes, to pharmaceutical compositions and to their use in therapy, in particular for the prophylaxis and therapy of tumour disorders.
    Type: Application
    Filed: February 8, 2011
    Publication date: February 14, 2013
    Applicant: BAYER INTELLECTUAL PROPERTY GMBH
    Inventors: Ningshu Liu, Kai Thede, Philip Lienau, Arne Scholz, Christoph-Stephan Hilger, Ulf Bömer, Maher Najjar, Knut Eis, Reiner Fischer, Wahed Ahmed Moradi
  • Near Infrared Imaging Agent
    Publication number: 20100129293
    Abstract: This invention relates to an in-vivo diagnostic method based on near infrared radiation (NIR radiation) that uses water-soluble dyes and their biomolecule adducts, each having specific photophysical and pharmaco-chemical properties, as a contrast medium for fluorescence and transillumination diagnostics in the NIR range, to new dyes and pharmaceuticals containing such dyes.
    Type: Application
    Filed: January 26, 2010
    Publication date: May 27, 2010
    Applicant: Institut fur Diagnostikforschung GmbH an der Freien Universitat Berlin
    Inventors: Kai Licha, Bjórn Riefke, Wolfhard Semmler, Ulrich Speck, Christoph-Stephan Hilger
  • Near infrared imaging agent
    Patent number: 7655217
    Abstract: This invention relates to an in-vivo diagnostic method based on near infrared radiation (NIR radiation) that uses water-soluble dyes and their biomolecule adducts, each having specific photophysical and pharmaco-chemical properties, as a contrast medium for fluorescence and transillumination diagnostics in the NIR range, to new dyes and pharmaceuticals containing such dyes.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: February 2, 2010
    Assignee: Institut fur Diagnosikforschung GmbH
    Inventors: Kai Licha, Björn Riefke, Wolfhard Semmler, Ulrich Speck, Christoph-Stephan Hilger
  • SELECTIVE TARGETING OF TUMOR VASCULATURE USING RADIOLABELLED ANTIBODY MOLECULES
    Publication number: 20090214423
    Abstract: A specific binding member that binds human ED-B, wherein the specific binding member is labelled with an isotope selected from the group consisting of 76Br, 77Br, 123I, 124I, 131I and 211At and comprises an antigen-binding site that comprises an antibody VH domain and an antibody VL domain, wherein the antibody VH domain is selected from the group consisting of the L19 VH domain, and a VH domain comprising a VH CDR1, a VH CDR2 and a VH CDR3, wherein the VH CDR3 is the L19 VH CDR3 of SEQ ID NO. 3, the VH CDR1 is optionally L19 VH CDR1 of SEQ ID NO. 1, and the VH CDR2 is optionally L19 VH CDR2 of SEQ ID NO. 2; and wherein the antibody VL domain is optionally selected from the group consisting of the L19 VL domain, and a VL domain comprising a VL CDR1, a VL CDR2 and a VL CDR3, wherein the VL CDR3 is the L19 VL CDR3 of SEQ ID NO. 6, the VL CDR1 is optionally L19 VL CDR1 of SEQ ID NO. 4, and the VL CDR2 is optionally L19 VL CDR2 of SEQ ID NO.
    Type: Application
    Filed: January 8, 2009
    Publication date: August 27, 2009
    Inventors: Laura Borsi, Enrica Balza, Barbara Carnemolla, Patrizia Castellani, Luciano Zardi, Matthias Friebe, Christoph-Stephan Hilger
  • In-vivo diagnostic method by near infrared radiation
    Patent number: 7445767
    Abstract: This invention relates to an in-vivo diagnostic method based on near infrared radiation (NIR radiation) that uses water-soluble dyes and their biomolecule adducts, each having specific photophysical and pharmaco-chemical properties, as a contrast medium for fluorescence and transillumination diagnostics in the NIR range, to new dyes and pharmaceuticals containing such dyes.
    Type: Grant
    Filed: March 22, 2006
    Date of Patent: November 4, 2008
    Assignee: Institut fur Diagnostikforschung GmbH an der Freien Universitat Berlin
    Inventors: Kai Licha, Björn Riefke, Wolfhard Semmler, Ulrich Speck, Christoph-Stephan Hilger
  • STENTS WITH A RADIOACTIVE SURFACE COATING, PROCESSES FOR THEIR PRODUCTION AND THEIR USE FOR RESTENOSIS PROPHYLAXIS
    Publication number: 20070032694
    Abstract: The invention relates to radioactive stents, characterized in that the stent is coated on the surface with the radioactive isotope, as well as processes for their production.
    Type: Application
    Filed: November 24, 2003
    Publication date: February 8, 2007
    Inventors: Ludger Dinkelborg, Friedhelm Blume, Christoph-Stephan Hilger, Dieter Heldmann, Johannes Platzek, Ulrich Niedballa, Heribert Miklautz, Ulrich Speck, Stephan Duda, Gunnar Tepe, Bernhard Noll, Heidemarie Goerner
  • Near infrared imaging agent
    Publication number: 20060165599
    Abstract: This invention relates to an in-vivo diagnostic method based on near infrared radiation (NIR radiation) that uses water-soluble dyes and their biomolecule adducts, each having specific photophysical and pharmaco-chemical properties, as a contrast medium for fluorescence and transillumination diagnostics in the NIR range, to new dyes and pharmaceuticals containing such dyes.
    Type: Application
    Filed: March 22, 2006
    Publication date: July 27, 2006
    Applicant: Institut fur Diagnostikforschung GmbH
    Inventors: Kai Licha, Bjorn Riefke, Wolfhard Semmler, Ulrich Speck, Christoph-Stephan Hilger
  • In-vivo diagnostic method by near infrared radiation
    Publication number: 20060165598
    Abstract: This invention relates to an in-vivo diagnostic method based on near infrared radiation (NIR radiation) that uses water-soluble dyes and their biomolecule adducts, each having specific photophysical and pharmaco-chemical properties, as a contrast medium for fluorescence and transillumination diagnostics in the NIR range, to new dyes and pharmaceuticals containing such dyes.
    Type: Application
    Filed: March 22, 2006
    Publication date: July 27, 2006
    Applicant: Institut fur Diagnostikforschung GmbH an der Freien Universitat Berlin
    Inventors: Kai Licha, Bjorn Riefke, Wolfhard Semmler, Ulrich Speck, Christoph-Stephan Hilger
  • In-vivo diagnostic method by means of near infrared radiation
    Patent number: 7025949
    Abstract: This invention relates to an in-vivo diagnostic method based on near infrared radiation (NIR radiation) that uses water-soluble dyes and their biomolecule adducts, each having specific photophysical and pharmaco-chemical properties, as a contrast medium for fluorescence and transillumination diagnostics in the NIR range, to new dyes and pharmaceuticals containing such dyes.
    Type: Grant
    Filed: May 7, 2001
    Date of Patent: April 11, 2006
    Assignee: Institut fur Diagnostikforschung GmbH an der Freien Universitat Berlin
    Inventors: Kai Licha, Bjorn Riefke, Wolfhard Semmler, Ulrich Speck, Christoph-Stephan Hilger